InspireMD Q3 2020 Earnings Report
Key Takeaways
InspireMD reported a revenue increase of 4.4% to $980,000 for the third quarter of 2020, compared to $939,000 in the same period of 2019. The increase was driven by a 69.0% increase in sales volume of MGuard EPS, offset by a 2.2% decrease in sales volume of CGuard Prime EPS. Gross profit increased by 132.8% to $298,000, and the net loss totaled $2,233,000, or $0.06 per basic and diluted share.
Third quarter financial results returned to pre-COVID revenue levels.
Strategic pathway to growth for CGuard EPS is focused on broadening market share and expanding into new countries.
Pivotal study in the United States is planned, with the addition of key advisors.
Developing a new advanced tool set of adjunctive delivery system options to drive adoption of CGuard EPS.